Collaboration between industry, research, universities, government, and organisations is crucial for vaccine development and addressing public health needs, with a focus on overcoming barriers, accelerating access to technologies, and enhancing public-private partnerships. This is emphasised by the program committee chair Jenny Herz and a program committee member Professor Jodie McVernon of the Inaugural Vaccine Value Chain Conference, who invited Australian Health Journal to attend.
For the first time, key decision-makers and thought leaders from government, industry, academia, NGOs, and representatives from the immunisation community converged in a 2 day conference in Sydney hosted by Biointelect, highlighting the transformative potential of collaborative innovation.
In talking to Australian Health Journal, Ms Herz spoke about the end to end value chain of vaccine development involving discovery, research, product development, clinical trials, regulatory and reimbursement processes, and community implementation, with a focus on understanding the community’s perspectives and needs. Collaboration between industry and academic research is crucial for overcoming challenges in vaccine development and commercialisation.
She reflects how the pandemic spurred innovation in vaccine development and clinical trials, revealing the need to address gaps and explore new pathways for accelerating access to technologies and medicine, with more venture capital available for funding oncology products than infectious diseases.
According to the Inaugural Program Committee, there are many aspects involved in the value chain of vaccines from discovery through to implementation. However, the understanding of all the challenges, barriers, and levers to streamline the value chain across all key stakeholders is fragmented and sometimes siloed in Australia’s federated system.
During the COVID-19 pandemic novel vaccines were developed globally in record time. Australia’s public health ecosystem pulled together, but the gaps became clear. Since then, there have been many lessons learnt and significant investment by jurisdictional and Federal Governments, the private sector and philanthropy into different parts of the ecosystem.
While Australia has strengths in many areas, such as discovery research, the knowledge and experience to translate discoveries effectively, to truly impact the health of the community, requires data availability, resources and know-how all along the value chain. Access to funding and skilled workforce remains fragmented across our ecosystem, and this affects Australia’s ability to capitalise on research strengths in infectious diseases and immunology.
Professor McVernon and Ms Herz talk about collaboration between public and private sectors being essential to address unmet needs, and funding for innovation to come from NGOs, philanthropy, or public money if it is not attractive to the private sector.
The consensus of opinions coming from the conference speakers and delegates was that Australia needs to take a national approach and present itself as a strong player in the international community to find its relevant place in the value chain.
-
Significant funding announced for NSW biomedical researchers
The Snow Medical Research Foundation (Snow Medical) has announced a new $24 million investment in three outstanding Australian biomedical researchers through its prestigious Snow Fellowships.
These Fellows will tackle major global health challenges spanning autoimmune disease, neurological disorders, and genetic disease. Their work addresses conditions that disproportionately affect vulnerable and underserved populations, including First Nations communities, while advancing precision medicine and translational care. Collectively, their research aims to deliver safer vaccines, better diagnostics, and more equitable genomic and neurological healthcare.
-
Changes in MBS bulk billing incentives address GP capacity in women’s health
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
-
From paediatric nursing to leadership & private hospital general management
With over 20 years of experience in the Australian and international healthcare sectors, Georgia Banks is a dedicated and results-driven health professional with a proven track record in clinical, financial, human resources, and strategic management. Passionate about delivering high-quality patient care, Georgia possesses an authentic leadership style that fosters engagement, collaboration, and continuous improvement.
Currently serving as General Manager at Hobart Private Hospital within Healthscope, Georgia has been instrumental in driving operational excellence, enhancing patient experience, and supporting staff development. Her leadership has played a key role in aligning hospital services with strategic priorities while fostering a culture of accountability and innovation.
